ECOG-ACRIN Cancer Research Group

ECOG-ACRIN Cancer Research Group Biomarker-driven research involving adults who have or are at risk of developing cancer

Clinical trial MM1OA-EA02, led by Dr. Jessica Altman of the Lurie Cancer Center, aims to improve results for older adult...
10/09/2026

Clinical trial MM1OA-EA02, led by Dr. Jessica Altman of the Lurie Cancer Center, aims to improve results for older adults with acute myeloid leukemia (AML). Learn more: https://bit.ly/mm1oa-ea02-study

Do you have newly diagnosed ? If so, you may be able to participate in this study of a new treatment approach. Learn mo...
10/09/2026

Do you have newly diagnosed ? If so, you may be able to participate in this study of a new treatment approach. Learn more about EAF223/GABLE here: https://bit.ly/gable-trial

Do you have newly diagnosed multiple myeloma and are either ineligible for or willing to delay stem cell transplantation...
10/08/2026

Do you have newly diagnosed multiple myeloma and are either ineligible for or willing to delay stem cell transplantation? If so, you may be eligible to participate in clinical trial EAA181/EQUATE. More info here: https://bit.ly/eaa181equate

Clinical trial EA8231, led by Monika Joshi, MD and Petros Grivas, MD, PhD, is a phase 3 randomized study exploring a new...
10/08/2026

Clinical trial EA8231, led by Monika Joshi, MD and Petros Grivas, MD, PhD, is a phase 3 randomized study exploring a new treatment approach for pts with treatment-refractory, locally-advanced or metastatic urothelial cancer. More information here: https://bit.ly/ea8231-study

Clinical study EA3191 is testing a new treatment approach for patients with squamous cell carcinoma of the head and neck...
10/08/2026

Clinical study EA3191 is testing a new treatment approach for patients with squamous cell carcinoma of the head and neck ( ) that has come back after initial therapy. Learn more: https://bit.ly/ea3191-study

10/07/2026

Learn more about this important study from PrECOG Cancer Research Group.

Progress in precision depends on shared resources. researchers are partnering with to profile paired primary and rec...
10/07/2026

Progress in precision depends on shared resources. researchers are partnering with to profile paired primary and recurrent breast tumors from two landmark trials, TAILORx and RxPONDER. During learn more: https://bit.ly/ea1241-blog

The usual treatment for with early-stage includes two surgeries. The EA6244 study asks: could one surgery + close mo...
10/07/2026

The usual treatment for with early-stage includes two surgeries. The EA6244 study asks: could one surgery + close monitoring be just as effective for some people? More info: https://bit.ly/ea6244-study

The Study, led by researchers from Stanford Cancer Institute, MD Anderson Cancer Center, & the National Cancer Institu...
10/07/2026

The Study, led by researchers from Stanford Cancer Institute, MD Anderson Cancer Center, & the National Cancer Institute, is testing new combinations of anti-cancer drugs, based on characteristics found in patients’ tumors or blood. Learn more: http://bit.ly/ComboMATCH

Urothelial cancer is the most common type of . The EA8192 study is evaluating durvalumab and chemotherapy for patients ...
10/06/2026

Urothelial cancer is the most common type of . The EA8192 study is evaluating durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. https://bit.ly/ea8192-trial

Address

Philadelphia, PA

Telephone

+12157893631

Website

,

Alerts

Be the first to know and let us send you an email when ECOG-ACRIN Cancer Research Group posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category